Analysis of platelet apheresis transfusion trends in Suzhou from 2017-2022
10.13303/j.cjbt.issn.1004-549x.2024.11.010
- VernacularTitle:2017—2022年苏州地区多次输注单采血小板患者特征分析
- Author:
Zhen LIU
1
;
Qi XIAO
1
;
Zihao XU
1
;
Yihan WANG
1
;
Yiming JIN
1
Author Information
1. Suzhou Blood center, Suzhou 215002, China
- Publication Type:Journal Article
- Keywords:
leukemia;
acute myeloid leukaemia (AML);
platelet transfusion refractoriness (PTR);
platelet compatibility transfusion
- From:
Chinese Journal of Blood Transfusion
2024;37(11):1275-1280
- CountryChina
- Language:Chinese
-
Abstract:
[Objective] To investigate the clinical characteristics of patients who underwent multiple platelet transfusions (≥2 times) in Suzhou over the past 5 years (2017-2022), as to provide new insights for patients requiring long-term and substantial platelet transfusions. [Methods] A retrospective analysis was conducted on the type of diseases, volume and frequency of platelet transfusions in patients who were hospitalized in Suzhou and received multiple (≥2 times) apheresis platelet transfusions from August 2017 to August 2022. Compatibility transfusions were also performed for a subset of acute myeloid leukaemia (AML) patients who completed HLA antibody testing and genotyping. [Results] From 2017 to 2022, the clinical consumption of platelets in Suzhou has increased annually (P<0.001), and patients who received apheresis platelets were mainly concentrated in hematological diseases represented by hematopoietic or lymphoid tissue tumors, especially AML patients (48.81%, 1 188/2 434). The age group with the highest per capita number of transfusions among AML patients was predominantly 21-30 years old (25 times per person). After genotype-compatible transfusion for eligible AML patients, the CCI significantly increased (P<0.001). [Conclusion] For male AML patients aged 21-30 and 61-70 in Suzhou, conducting platelet antibody screening and genetic testing before platelet transfusion can improve the efficiency of transfusion, reduce the incidence of PTR, and save blood resources through personalized matching transfusions.
